Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome

Completed 20 enrolled Garvan Institute of Medical Research

RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to investigate the effects of a GLP-1 agonist on satiety hormones in patients with Prader-Willi Syndrome (genetic defect causing obesity).

Timeline

Start: 2007-10
Primary completion: 2008-09
Completion: 2008-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Exenatide	Peptide	10 ug	Subcutaneous

Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome

Summary

Timeline

Drugs

Indications